Opinion

Video

Selection and Sequencing of JAK Inhibitors for Patients With MF

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of using the full dose for best efficacy and how different scenarios might influence the choice and sequencing of these drugs in practice.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Julie M. Vose, MD, MBA
6369343864112
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Carrie L. Kitko, MD
Peter Riedell, MD
Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Al Malki
Related Content
Imetelstat for Transfusion-Dependent Anemia in MDS | Image credit: © Fotograf – stock.adobe.com
March 12th 2025

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Cema-Cel in R/R LBCL | Image Credit: © LASZLO – stock.adobe.com
March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.
March 9th 2025

The OncFive: Top Oncology Articles for the Week of 3/2

Image credit: © Fotograf – stock.adobe.com
March 6th 2025

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL